These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 10910797)

  • 41. Symptomatic remission and cognitive impairment in first-episode schizophrenia: a prospective 3-year follow-up study.
    Chang WC; Ming Hui CL; Yan Wong GH; Wa Chan SK; Ming Lee EH; Hai Chen EY
    J Clin Psychiatry; 2013 Nov; 74(11):e1046-53. PubMed ID: 24330905
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Computer-assisted cognitive rehabilitation reduces negative symptoms in the severely mentally ill.
    Bellucci DM; Glaberman K; Haslam N
    Schizophr Res; 2003 Feb; 59(2-3):225-32. PubMed ID: 12414079
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clozapine in treatment-resistant patients with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder: a naturalistic 48-month follow-up study.
    Ciapparelli A; Dell'Osso L; Bandettini di Poggio A; Carmassi C; Cecconi D; Fenzi M; Chiavacci MC; Bottai M; Ramacciotti CE; Cassano GB
    J Clin Psychiatry; 2003 Apr; 64(4):451-8. PubMed ID: 12716249
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Adjunctive psychosocial therapies for the treatment of schizophrenia.
    Patterson TL; Leeuwenkamp OR
    Schizophr Res; 2008 Mar; 100(1-3):108-19. PubMed ID: 18226500
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Preliminary evaluation of cognitive adaptation training to compensate for cognitive deficits in schizophrenia.
    Velligan DI; Mahurin RK; True JE; Lefton RS; Flores CV
    Psychiatr Serv; 1996 Apr; 47(4):415-7. PubMed ID: 8689375
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Cognitive deficits in schizophrenia and other psychotic disorders].
    Fagerlund B; Glenthøj BY
    Ugeskr Laeger; 2008 Nov; 170(46):3770-2. PubMed ID: 19014728
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning.
    Kinon BJ; Noordsy DL; Liu-Seifert H; Gulliver AH; Ascher-Svanum H; Kollack-Walker S
    J Clin Psychopharmacol; 2006 Oct; 26(5):453-61. PubMed ID: 16974184
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and effectiveness of individual family intervention on social and clinical functioning and family burden in severe schizophrenia: a 2-year randomized controlled study.
    Girón M; Fernández-Yañez A; Mañá-Alvarenga S; Molina-Habas A; Nolasco A; Gómez-Beneyto M
    Psychol Med; 2010 Jan; 40(1):73-84. PubMed ID: 19490746
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cognitive rehabilitation with patients having persistent, severe psychiatric disabilities.
    Lewis L; Unkefer EP; O'Neal SK; Crith CJ; Fultz J
    Psychiatr Rehabil J; 2003; 26(4):325-31. PubMed ID: 12739903
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia.
    Fenton WS; Dickerson F; Boronow J; Hibbeln JR; Knable M
    Am J Psychiatry; 2001 Dec; 158(12):2071-4. PubMed ID: 11729030
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cognitive enhancement therapy for early-course schizophrenia: effects of a two-year randomized controlled trial.
    Eack SM; Greenwald DP; Hogarty SS; Cooley SJ; DiBarry AL; Montrose DM; Keshavan MS
    Psychiatr Serv; 2009 Nov; 60(11):1468-76. PubMed ID: 19880464
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Psychosocial treatments to promote functional recovery in schizophrenia.
    Kern RS; Glynn SM; Horan WP; Marder SR
    Schizophr Bull; 2009 Mar; 35(2):347-61. PubMed ID: 19176470
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Symptoms, cognitive functioning, and adaptive skills in geriatric patients with lifelong schizophrenia: a comparison across treatment sites.
    Harvey PD; Howanitz E; Parrella M; White L; Davidson M; Mohs RC; Hoblyn J; Davis KL
    Am J Psychiatry; 1998 Aug; 155(8):1080-6. PubMed ID: 9699697
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dissociating self-reported cognitive complaint from clinical insight in schizophrenia.
    Bayard S; Capdevielle D; Boulenger JP; Raffard S
    Eur Psychiatry; 2009 May; 24(4):251-8. PubMed ID: 19324531
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Determinants of work outcome in neuroleptic-resistant schizophrenia and schizoaffective disorder: cognitive impairment and clozapine treatment.
    Kaneda Y; Jayathilak K; Meltzer H
    Psychiatry Res; 2010 Jun; 178(1):57-62. PubMed ID: 20452677
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of the selective norepinephrine reuptake inhibitor reboxetine on cognitive dysfunction in schizophrenia patients: an add-on, double-blind placebo-controlled study.
    Poyurovsky M; Faragian S; Fuchs C; Pashinian A
    Isr J Psychiatry Relat Sci; 2009; 46(3):213-20. PubMed ID: 20039523
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The retinoid X receptor agonist bexarotene relieves positive symptoms of schizophrenia: a 6-week, randomized, double-blind, placebo-controlled multicenter trial.
    Lerner V; Miodownik C; Gibel A; Sirota P; Bush I; Elliot H; Benatov R; Ritsner MS
    J Clin Psychiatry; 2013 Dec; 74(12):1224-32. PubMed ID: 24434091
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Predicting medication-free treatment response in acute psychosis: cross-validation from the Finnish Need-Adapted Project.
    Bola JR; Lehtinen K; Aaltonen J; Räkköläinen V; Syvälahti E; Lehtinen V
    J Nerv Ment Dis; 2006 Oct; 194(10):732-9. PubMed ID: 17041284
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [First-episode psychosis, cognitive difficulties and remediation].
    Vidailhet P
    Encephale; 2013 Sep; 39 Suppl 2():S83-92. PubMed ID: 24084427
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Recovery in schizophrenia: focus on neurocognitive functioning.
    Zaytseva Y; Gurovich IY; Goland E; Storozhakova YA
    Psychiatr Danub; 2012 Sep; 24 Suppl 1():S172-5. PubMed ID: 22945216
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.